Buparlisib (BKM120, NVP-BKM120)

目录号:S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Phase 2。

规格 价格 库存 购买数量  
RMB 2227.95 现货
RMB 1400.12 现货
RMB 2607.65 现货
RMB 7928.28 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献38篇:

客户使用该产品的6个实验数据:

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Phase 2。
特性 BKM120是可用于口服的生物有效的PI3K抑制剂。
靶点
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外研究

BKM120作用于解除PI3K调节的细胞系,包括A2780, U87MG, MCF7和DU145时,具有抗增殖活性,GI50为0.1-0.7 nM。[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡,导致G1期细胞增多,S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡,且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。[2]BKM120作用于人类胃癌细胞系,降低mTOR下游信号,具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系,可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞,诱导凋亡,具有协同效应,但是作用于KRAS野生型细胞没有这种效果。[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 Mn7YR5l1d3SxeHnjJGF{e2G7 MUS3NkBp MYPEUXNQ MmPxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?= M37kNlI1QTByMk[2
DU145 NUnmOGU5S3m2b4TvfIlkKEG|c3H5 NUTEV5p1PzJiaB?= M4m4XGROW09? NFy3SGxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCneIDy[ZN{cW6pIFzLRlEhdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFQ{PSEQvF2= M2P1fFI1QTByMk[2
A2780 Mn35R5l1d3SxeHnjJGF{e2G7 M2fCNFczKGh? NXzsOWR5TE2VTx?= MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCDMke4NEBk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2N|Uh|ryP Mm[5NlQ6ODB{Nk[=
U87MG MXrDfZRwfG:6aXOgRZN{[Xl? NXjWV4dPPzJiaB?= MXLEUXNQ M2niU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY6QCEQvF2= Mm[wNlQ6ODB{Nk[=
A2780 M3j4S2Z2dmO2aX;uJGF{e2G7 M3PVR|EhcA>? MWjEUXNQ M4mybmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6wOVUh|ryP NVXXXHB7OjR7MECyOlY>
DU145 M{m5b2Z2dmO2aX;uJGF{e2G7 Mn\6NUBp Ml7OSG1UVw>? MXzJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gSHUyPDViY3XscJMhcGG{Yn;ybY5oKEyNQkGgcZV1[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEezJO69VQ>? NYL2co9kOjR7MECyOlY>
A2780 NE\FfFFHfW6ldHnvckBCe3OjeR?= M3XXN|EhcA>? NUixfZQxTE2VTx?= NEC5R5BKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDFR|UxKG:oIECuNFc1KM7:TR?= MV:yOFkxODJ4Nh?=
MCF7 NEHGTmJHfW6ldHnvckBCe3OjeR?= M2jrTVEhcA>? Mo[zSG1UVw>? NE\1[JVKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hf2m2aDDFR|UxKG:oIECuNUDPxE1? MU[yOFkxODJ4Nh?=
U87MG M{PuZWZ2dmO2aX;uJGF{e2G7 MlTQNUBp NHH5SnNFVVOR NUHVW2ZJUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?= NITYV4szPDlyMEK2Oi=>
A2780 NXLT[IVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDPN2hFPzJiaB?= MonFSG1UVw>? NUjrepVITUN3ME2wMlUzKM7:TR?= NEDQdnEzPDlyMEK2Oi=>
SKMES-1 M2TxZ2N6fG:2b4jpZ{BCe3OjeR?= M1\YTFEh|ryP MXW3NkBp M1LKUmlv\HWlZYOgZ4VtdCCmZXH0bC=> Mn[0NlYxOTN|MUi=
H596 Mm\VSpVv[3Srb36gRZN{[Xl? Mn\4NUDPxE1? MVjJcZBicXK|IHPlcIwhdWmpcnH0bY9v NHLHZ5IzPjBzM{OxPC=>
HCC2450 NXLJVIxSTnWwY4Tpc44hSXO|YYm= NIrUe48yKM7:TR?= M1;vRmlueGGrcoOgZ4VtdCCrbo\hd4lwdg>? M{G2U|I3ODF|M{G4
A549 MW\GeY5kfGmxbjDBd5NigQ>? MVu1NFAhdk1? M{LEVVQ5KGh? M2XhXGROW09? Ml3ITY5pcWKrdIOgRYt1KGGldHn2ZZRqd25? NFj1[oMzPTl|N{K5PS=>
A549 M{S4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxJO69VQ>? MW[3NkBp MlfzSG1UVw>? M16wVmlvcGmkaYTzJINmdGxiZ4Lve5Rp Ml;6NlU6Ozd{OUm=
H522 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPV[W8yKM7:TR?= NVuwb|g6PzJiaB?= MlPCSG1UVw>? NUHpS|dCUW6qaXLpeJMh[2WubDDndo94fGh? NWHTNHBiOjV7M{eyPVk>
LNCaP MoHJSpVv[3Srb36gRZN{[Xl? NGXO[ZAyKM7:TR?= NVzrNIdwW3WycILld5NmeyCyLVHLWEBt\X[nbIO= MXyyOVM3ODd7OR?=
LNCaP95 Mn3rSpVv[3Srb36gRZN{[Xl? NHLVfG8yKM7:TR?= MVrTeZBxemW|c3XzJJAuSUuWIHzleoVtew>? MXKyOVM3ODd7OR?=
HCT-15 NX3HOXV{SXCxdH;zbZMhSXO|YYm= NXvibVIxOTBizszN MkLPOFghcA>? Ml7wSG1UVw>? NFPDWllKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVUh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MlfSNlUyPTJ{NEW=
HCT-116 NXO1cGNWSXCxdH;zbZMhSXO|YYm= M2\jd|ExKM7:TR?= M4f0[FQ5KGh? NGPyfIpFVVOR M37xVWlv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xNVYh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M4jqNVI2OTV{MkS1
NCI-H460 MnrDRZBwfG:|aYOgRZN{[Xl? M132clExKM7:TR?= NGTVZZo1QCCq MkH1SG1UVw>? NGXRXIxKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCQQ1mtTFQ3OCClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S|cH;0JI12fGG2aX;u M3PGRlI2OTV{MkS1
SKOV-3 Ml7jRZBwfG:|aYOgRZN{[Xl? NF30WWoyOCEQvF2= NVX5fYcyPDhiaB?= M2rae2ROW09? NYXR[IVyUW6mdXPld{BieG:ydH;zbZMhcW5iU1vPWk0{KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= Ml:yNlUyPTJ{NEW=
BSY-1 M335VmFxd3Sxc3nzJGF{e2G7 M4PFWlExKM7:TR?= MlPMOFghcA>? M1fQU2ROW09? NUO1R|NDUW6mdXPld{BieG:ydH;zbZMhcW5iQmPZMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M4jXWVI2OTV{MkS1
MKN-1 M{S3dWFxd3Sxc3nzJGF{e2G7 M37oOlExKM7:TR?= MWG0PEBp MmO2SG1UVw>? M4LsWGlv\HWlZYOgZZBweHSxc3nzJIlvKE2NTj2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NInwR5QzPTF3MkK0OS=>
NCI-H522 MofrRZBwfG:|aYOgRZN{[Xl? NV\HfHUxOTBizszN M37q[VQ5KGh? NYTzVWFVTE2VTx?= NGP3fZVKdmS3Y3XzJIFxd3C2b4Ppdy=> MmrvNlUyPTJ{NEW=
OVCAR-3 NHHKb5FCeG:2b4Ppd{BCe3OjeR?= NGTGNpkyOCEQvF2= NV7kNWhGPDhiaB?= MnezSG1UVw>? NEi2W4pKdmS3Y3XzJIFxd3C2b4Ppdy=> M2i4XlI2OTV{MkS1
HBC-5 NID5O3pCeG:2b4Ppd{BCe3OjeR?= MUmxNEDPxE1? MlLmOFghcA>? MVrEUXNQ M1;DbWlv\HWlZYOgZZBweHSxc3nz NGi5eXQzPTF3MkK0OS=>
RXF-631L Mm\vRZBwfG:|aYOgRZN{[Xl? MUWxNEDPxE1? NFWyNow1QCCq MYjEUXNQ NIe2T3RKdmS3Y3XzJIFxd3C2b4Ppdy=> NVnWPVQ4OjVzNUKyOFU>
MKN-45 M4nDbWFxd3Sxc3nzJGF{e2G7 NYPhTZI{OTBizszN M3rQRVQ5KGh? M{TieGROW09? MV;JcoR2[2W|IHHwc5B1d3Orcx?= MY[yOVE2OjJ2NR?=
BON-1 NHm1NGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L6PFUxOCCwTR?= MWixNEBl M1\lbGROW09? MkL1TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MVqyOVAzPjJ7Mh?=
BON-1 MmO3SpVv[3Srb36gRZN{[Xl? MoXoOVAxKG6P M{S4RlQhcA>? MVfEUXNQ M{\kbGlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= M1TJXFI2ODJ4Mkmy
QGP-1 M3PieGZ2dmO2aX;uJGF{e2G7 MkPNOVAxKG6P MVW0JIg> M{foOmROW09? MYTJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd| MU[yOVAzPjJ7Mh?=
Huh7 NXTaUJU1TnWwY4Tpc44hSXO|YYm= MnvzNUDPxE1? MkLkNUBp NXT2[WU6TE2VTx?= MXvJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>? NH;lWIczPTByNESwNy=>
BNL MoD1SpVv[3Srb36gRZN{[Xl? NFLGSIkyKM7:TR?= NHjIWYwyKGh? NFrBeGdFVVOR NXS4NoJzUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFN4 M1zoU|I2ODB2NECz
MDA-MB-175 M4G0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nlWVEh|ryP NG\Ze|U2KGR? NUPyUFhZTE2VTx?= NIrhdmFKSzVyPEGg{txO NFnzPZUzPDh5OUe5Oi=>
MDA-MB-134 NXjDfHpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33i[FEh|ryP NXHxOotDPSCm M4LuPWROW09? NXT4RWU2UUN3MEyxJO69VQ>? M3PI[lI1QDd7N{m2
HCC1500 NV7pdGxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnONUDPxE1? MlTLOUBl M1fJV2ROW09? MlXCTWM2ODxzIN88US=> NEDCPHczPDh5OUe5Oi=>
EFM-19 NIHaem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjXS3ZXOSEQvF2= NV\WOJpVPSCm NXrwOJBSTE2VTx?= MXHJR|UxRDFizszN NWHGdpRwOjR6N{m3PVY>
ZR-75-30 NXL6bGgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7TNUDPxE1? MXG1JIQ> M2LucWROW09? MV\JR|UxRDFizszN NVyw[4tkOjR6N{m3PVY>
MDA-MB-361 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nwRVEh|ryP NYXlSnBIPSCm M4G1dWROW09? NY\xe3R1UUN3MEyxJO69VQ>? NXnWOZdGOjR6N{m3PVY>
T-47D NITwRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH2S2kyKM7:TR?= NFPpT4Q2KGR? Mn3MSG1UVw>? M1vvT2lEPTB:MTFOwG0> Ml70NlQ5Pzl5OU[=
SK-BR-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGniZ4cyKM7:TR?= NVK0OGRrPSCm M{LT[2ROW09? MWDJR|UxRDFizszN MVOyOFg4QTd7Nh?=
UACC-732 NVvrOlJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXIcYZoOSEQvF2= NUP2[I9PPSCm MX;EUXNQ MmewTWM2ODxzIN88US=> NH65[4kzPDh5OUe5Oi=>
BT-474 NIfoSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrXNUDPxE1? NFnVV5M2KGR? M3rs[WROW09? MlLpTWM2ODxzIN88US=> NG\GN5YzPDh5OUe5Oi=>
HCC202 MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxJO69VQ>? NGrzToE2KGR? M4TqTGROW09? MkjRTWM2ODxzIN88US=> M2TKTFI1QDd7N{m2
MCF7 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fxe|Eh|ryP M33QU|Uh\A>? NVL4fZNHTE2VTx?= NHO2R4JKSzVyPEGg{txO NEXFSHQzPDh5OUe5Oi=>
MDA-MB-415 M3vlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnroNUDPxE1? M3rybVUh\A>? MV7EUXNQ MkPnTWM2ODxzIN88US=> NXzIcnF3OjR6N{m3PVY>
MDA-MB-453 NELMdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrrNUDPxE1? MXi1JIQ> MmDoSG1UVw>? NI[yT2JKSzVyPEGg{txO MknPNlQ5Pzl5OU[=
ZR-75-1 NXjBPHZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjmNFR6OSEQvF2= NHTqeIQ2KGR? MkO4SG1UVw>? M{nUZ2lEPTB:MTFOwG0> M1fLWlI1QDd7N{m2
HCC38 NYfnblJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\1[oEyKM7:TR?= MkPBOUBl NELGUIJFVVOR M3j5NmlEPTB:MTFOwG0> Moj6NlQ5Pzl5OU[=
HCC1419 NXrMfY1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\QOFEh|ryP M{\YN|Uh\A>? MmjFSG1UVw>? NFHzNohKSzVyPEGg{txO NHS0VJEzPDh5OUe5Oi=>
UACC-812 NInYXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6xJO69VQ>? M3\Yd|Uh\A>? MYDEUXNQ MVXJR|UxRDFizszN NIrIW|czPDh5OUe5Oi=>
HCC1187 NYC1XVIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHPcWdFOSEQvF2= Mo[5OUBl NXHOUI5XTE2VTx?= NVi0UpN1UUN3MEyxJO69VQ>? MW[yOFg4QTd7Nh?=
KPL-1 NITiZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPpNUDPxE1? M1jucVUh\A>? MYDEUXNQ M1Hvc2lEPTB:MTFOwG0> Mk\ZNlQ5Pzl5OU[=
SUM-225 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPxNUDPxE1? NH3aOm82KGR? M{LXe2ROW09? NF:xOJlKSzVyPEGg{txO MYGyOFg4QTd7Nh?=
EFM-192A NEDpV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWxJO69VQ>? MY[1JIQ> NFXqNoRFVVOR NGHUSHdKSzVyPEGg{txO MUiyOFg4QTd7Nh?=
JIMT-1 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHuTnhiOSEQvF2= MYm1JIQ> NVHrOHB4TE2VTx?= Mn[0TWM2ODxzIN88US=> M3rYe|I1QDd7N{m2
HCC1143 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TxNlEh|ryP MY[1JIQ> NFTlZ3BFVVOR Mn;5TWM2ODxzIN88US=> Mk\INlQ5Pzl5OU[=
HCC2218 NXPaXXQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILCN2cyKM7:TR?= NHrqcnA2KGR? NVLicW51TE2VTx?= NHLobpdKSzVyPEGg{txO MWCyOFg4QTd7Nh?=
MDA-MB-468 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXLRlVIOSEQvF2= NX;iVFJGPSCm M3jKU2ROW09? NVuxcmZiUUN3MEyxJO69VQ>? M1zNblI1QDd7N{m2
BT-20 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r5OVEh|ryP MnfaOUBl NIrhdHpFVVOR MlzpTWM2ODxzIN88US=> NF:2W2YzPDh5OUe5Oi=>
MDA-MB-435 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4niVlEh|ryP M3\0b|Uh\A>? M2e0N2ROW09? MV7JR|UxRDFizszN Mn\WNlQ5Pzl5OU[=
BT-549 M2fib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETrRYUyKM7:TR?= M2j4SVUh\A>? NILzbXVFVVOR NG[3RZNKSzVyPEGg{txO MXGyOFg4QTd7Nh?=
HCC1806 NYix[WMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[xJO69VQ>? M3PBXlUh\A>? Mn;ISG1UVw>? MmXSTWM2ODxzIN88US=> NEG3fVAzPDh5OUe5Oi=>
HCC1937 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjYVFAyKM7:TR?= M17ielUh\A>? NF\Ce2xFVVOR MVjJR|UxRDFizszN M{PNfFI1QDd7N{m2
Hs578T MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\6eG5tOSEQvF2= NFGze2M2KGR? MXzEUXNQ Mm\uTWM2ODxzIN88US=> M4X6Z|I1QDd7N{m2
LN18 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXnZ4JwOjBizszN M{fHe|czKGh? MWnEUXNQ MVnJR|UxRDVizszN NGrWbnQzPDd2MUC3OC=>
LN229 Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;KT4lzOjBizszN MlTxO|IhcA>? M1;VSWROW09? NEHUN|hKSzVyPEWg{txO M2nxbVI1PzRzMEe0
LNZ308 NUfYOIJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2mxVlIxKM7:TR?= MlfzO|IhcA>? M4j0c2ROW09? MkS0TWM2ODx3IN88US=> MYSyOFc1OTB5NB?=
T98G NF;XVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TTeVIxKM7:TR?= M3nxRlczKGh? NH75R2VFVVOR M4HDXmlEPTB:NTFOwG0> NFHqO4MzPDd2MUC3OC=>
U87 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGyNEDPxE1? MVm3NkBp M{K3d2ROW09? MWjJR|UxRDVizszN MkD2NlQ4PDFyN{S=
LN18 MX7GeY5kfGmxbjDBd5NigQ>? NYXLUIs4PSEQvF2= M{jsNFI1KGh? NEjQfHZFVVOR MUfJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV NHjYR44zPDd2MUC3OC=>
LNZ308 NGf1eIdHfW6ldHnvckBCe3OjeR?= NGj1OnM2KM7:TR?= MmDxNlQhcA>? MY\EUXNQ NYOxbWNOUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MYeyOFc1OTB5NB?=
Saos-2 NGDhcVhHfW6ldHnvckBCe3OjeR?= MXu1NEDPxE1? MW[0PEBp M1\6TmlvcGmkaYTzJINmdGxiaX72ZZNqd25? MlznNlQ4Ojd4NkC=
MG-63 NGWzemxHfW6ldHnvckBCe3OjeR?= Ml[zOVAh|ryP NEHY[nU1QCCq NF6wcHhKdmirYnn0d{Bk\WyuIHnueoF{cW:w NVO3cGhnOjR5Mke2OlA>
SJSA-1 NGKxeoZHfW6ldHnvckBCe3OjeR?= MXm1NEDPxE1? NYXG[nBpPDhiaB?= Mlr5TY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? MV6yOFczPzZ4MB?=
Saos-2 MVHGeY5kfGmxbjDBd5NigQ>? NVLRXmd{PTBizszN NV;xVWtFPDhiaB?= NIfpUINKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v NVfnXYpVOjR5Mke2OlA>
MG-63 MWTGeY5kfGmxbjDBd5NigQ>? MVG1NEDPxE1? M2r6ZlQ5KGh? MWDJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u MVKyOFczPzZ4MB?=
SJSA-1 MojZSpVv[3Srb36gRZN{[Xl? NXvTNmNLPTBizszN NIfuXmI1QCCq NH;nNpZKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v MVOyOFczPzZ4MB?=
Saos-2 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[1NEDPxE1? M3f0T|Q5KGh? MnLlTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NIDWZowzPDd{N{[2NC=>
MG-63 NHL3PVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDkWpA4PTBizszN MkG0OFghcA>? M2iwPWlvcGmkaYTzJINmdGxidnnhZoltcXS7 NVHwe3hxOjR5Mke2OlA>
SJSA-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfQTVQ2OCEQvF2= Mk[4OFghcA>? M1j6cmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NYTEN|JMOjR5Mke2OlA>
FaDu NVS4UXdnTnWwY4Tpc44hSXO|YYm= MoLYOUDPxE1? Ml\6NlQhcA>? NFvDUoRFVVOR Ml3wVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= M3XmbVI1PjNzMUS3
EMT6 MUHGeY5kfGmxbjDBd5NigQ>? NHmxdZk2KM7:TR?= M3TZZlI1KGh? MVrEUXNQ NE\tbYdT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> M1XxZ|I1PjNzMUS3
HCT116 NIrKRodHfW6ldHnvckBCe3OjeR?= MlH1OUDPxE1? NGjWdWkzPCCq NHfSNZBFVVOR M4T1fHJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u M17GOFI1PjNzMUS3
U87 MoLpSpVv[3Srb36gRZN{[Xl? MmH3OUDPxE1? MWmyOEBp MV3EUXNQ M3rZdXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u M1vTSlI1PjNzMUS3
GBM NFLGOXJCeG:ydH;zbZMhSXO|YYm= M3e3b|LPxE1? MWO0PIg> MXnEUXNQ M3S3eYlv\HWlZXSgbIlocGW{IHzleoVteyCxZjDhdI9xfG:|aYOsJIFv\CCmZXPy[YF{\WRiY3XscEB3cWGkaXzpeJk> NVTrb4tVOjR3MEC0PVI>
BON M{O4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj4OYgyNTYQvF2= NHy1R2Q4Omh? NUfmfWYz\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MX6yOFQ1OzV{Mx?=
BON MUnBdI9xfG:|aYOgRZN{[Xl? MoXaNU02|ryP MYmyOIg> NInqU2dqdmO{ZXHz[ZMh[XCxcITvd4l{ NV\z[3cyOjR2NEO1NlM>
H1975 NV3YU4FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUiwMlMuQS54zszN NVzoc25yPzKq Mo\ESG1UVw>? M1nBbGlEPTB;MT6zPFXPxE1? MlSwNlQ{Ozd6NE[=
H1975 MmrFRZBweHSxc3nzJGF{e2G7 MUGy{txO NHu2VmczPGh? Ml61SG1UVw>? MX3pcoNz\WG|ZYOgZZBweHSxc3nzJJJifGVic3nncolncWOjboTsfS=> M2joVFI1OzN5OES2
T-ALL MYHBdI9xfG:|aYOgRZN{[Xl? MXHi[ZR4\WWwIEGuOEBidmRiNT6zJI1OKGG2IEK0bEBidmRiMD65JIFv\CB3LkWgcW0h[XRiNEjoJIlvKGSrZn\ldoVvfCClZXzsJIxqdmV? NV7DUpVuOjRib4KgOFhp M3H4WGROW09? NYDwTo9R[W[oZXP0d{B1cGViUFmzT{Bx[XSqd3H5JIlvKFRvQVzMJINmdGxibHnu[ZM> NVK3eJNoOjR|MUC3N|Y>
BCR-ABL MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOwMlI2NTFyzszN M{\4[VRl MmXRd4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>? MnjaNlQzPDR4MUK=
LC-1/SQSF MVLGeY5kfGmxbjDBd5NigQ>? NGnq[oU{|ryP M2XpTVI1cA>? MWnEUXNQ Mo\a[IVkemWjc3WgUnJHOiCycn;0[YlvKGyndnXs NVvSO5lFOjN7OECwPVM>
Primary CLL cells NFvrOZJCeG:ydH;zbZMhSXO|YYm= MUCxMVEx|ryP MlnXOFhp MXvpcoR2[2W|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz NUn5OpgzOjN6NUC4NFc>
Primary CLL cells MXPLbY5ie2ViQYPzZZk> NVznZVB4Os7:TR?= NF\XXpk{OG2rbh?= NFvWVoll\WO{ZXHz[YQhWEl|SzDhZ5Rqfmm2eR?= MUOyN|g2ODhyNx?=
Primary CLL cells MV7DfZRwfG:6aXOgRZN{[Xl? M4fnd|LPxE1? MknyNlRp MWTpcoR2[2W|IHPlcIwh[3m2b4TvfIlkcXS7 NHG2fHczOzh3MEiwOy=>
human NSCLC cell lines MmW0RZBweHSxc3nzJGF{e2G7 M1PrRlAvOTJ3LUVOwG0> M{j4dFI1cA>? NXT2dFMxTE2VTx?= MVrJR|UxeyC{YX7n[ZMh\nKxbTCwMlQuOs7:TR?= MmnVNlM2PjJ2N{K=
human HCC cell lines M3;SdGNmdGxidnnhZoltcXS7IHHzd4F6 NFLWbZUxNjByNT2x{txO M2\CPVQ5cA>? MlqzTWM2OD1zzszN NYDXUWdFOjN2OEm5PVk>
Huh7 NUHFRYJqU2mwYYPlJGF{e2G7 MlXwNe69VQ>? MX[0PIg> MkjOd4lodmoxrJHjZY51dHlicnXkeYNmeyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0 M2nnO|I{PDh7OUm5
SK-HEP1 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxMVIx|ryP NFnySo84Omh? MXLEUXNQ NUHzOJBSUUN3MP-8oFHPxE1? MYmyN|Q4QTF|Nh?=
786-0 NVviSFNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXRcpljOS1{MN88US=> M1rPTVczcA>? NGXDVlJFVVOR MkjKTWM2OO,:nEJOwG0> M4e0bFI{PDd7MUO2
JVM2 Mnz6R5l1d3SxeHnjbZR6KGG|c3H5 NFuzSZUxNjJvMkFOwG0> MUW3Nog> NHPT[nJFVVOR M1jDfmlEPTB;MD65{txO NH7wNVczOzJ|OE[zPS=>
EHEB M3W2emN6fG:2b4jpZ4l1gSCjc4PhfS=> NGj3eFMxNjJvMkFOwG0> NIj1[Ys4Omh? NEi0PZhFVVOR NFXIc5dKSzVyPUCuO:69VQ>? MXqyN|I{QDZ|OR?=
MEC2 NH3rbVdEgXSxdH;4bYNqfHliYYPzZZk> Ml\XNE4zNTJyzszN MX23Nog> NX3wUGlbTE2VTx?= NITCSlRKSzVyPUCuO:69VQ>? M4TscFI{OjN6NkO5
primary B-CLL lymphocytes NFHHOHlCeG:ydH;zbZMhSXO|YYm= MnjGTWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? M{LRW|I1cA>? M3LjSWROW09? NHv6NmdKSzVy78{cN:69VSCob4KgZYxtKHCjdHnlcpR{ MWGyN|I{QDZ|OR?=
primary B-CLL lymphocytes M4Hj[2tqdmG|ZTDBd5NigQ>? MVfJR|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m NU[z[JFLOjSq MoXIbY5pcWKrdIOgdFcxWz[NID[gOGUuSlBzIHX4dJJme3Orb36= NE\ZT4MzOzJ|OE[zPS=>
human NSCLC NHy1TlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XOW|AvPS1{zszN MmL1O|Jp NV\PT4lDUUN3ME2x{txO NWTZfYduOjJ5OEGzPVM>
human NSCLC MmX6T4lv[XOnIFHzd4F6 MYCx{txO MU[yOIg> M2DscYlvcGmkaYTzJJRp\SCDa4SvcXRQWiC|aXfuZYxqdmdicHH0bJdigSCjdDCzbEBi\nSncjD0doVifG2nboS= MYWyNlc5OTN7Mx?=
Y1 cell line MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2xNE4y|ryPL{JOwG0> MUOyOIg> NF;VXnhFVVOR MXHpcohq[mm2czC2NQ+9jSClZXzsJJZq[WKrbHn0fUBqdiCPeXOtV4N1ei22cnHud4Zm[3SnZDDj[Yxtew>? NU\PVVY5OjJ4OUK5NFQ>
PIK3CA-mutant MCF7 NUfkeXBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j2[2dKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P MWW3Nog> M3LOU2dKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P MUeyNlY2Ozl4Nx?=
PIK3CA-mutant MCF7 MYHLbY5ie2ViQYPzZZk> MoTFTWM2OD1zMUVCtVNvVQ>? NYqxcFM3PzKq NGrEcoJKSzVyPUGxOOKyO26PIHnuJJJm\HWlaX7nJGFsfCCyaH;zdIhwenmuYYTpc44hdGW4ZXzz NHfteWozOjZ3M{m2Oy=>
MCF7-myr-Akt MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD3S2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1? NUHxSmJUPzKq MVLHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? MWKyNlY2Ozl4Nx?=
colon cancer cell lines MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCwMVEx|ryP NXSyRW1uPzKq M3TkRWROW09? M{Ta[2lEPTB;Md88US=> MnnmNlI2PDN6NUe=
gastric cancer cell lines M3zZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\5NE0yOM7:TR?= NGLMVGM4Omh? NEXoWY9FVVOR NVTabmtHUUN3ME2yMVXPxE1? MVmyNlU1Ozh3Nx?=
HCT-116/HT-29/MKN-45 MmC4RZBweHSxc3nzJGF{e2G7 MmT2Nu69VQ>? NF3sdYs1QGh? M3v1dZNpcW[2IHnuJGczKHCqYYPl MUmyNlU1Ozh3Nx?=
HT-29 and HCT-116 NYLJOGVNS2G|cHHz[UBie3OjeR?= NHjYNFA2|ryP NInn[VQzPGh? NF70ZnZqdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm= M{GxVVIzPTR|OEW3
MM cell lines Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny1NVDPxE1? MYqyOIg> NVriOlNETE2VTx?= NHrmcZFKSzVyII\hdolmeyCjbX;u[{BlcW[oZYLlcpQh[2WubDDsbY5meyCrbjD0bY1mKGGwZDDkc5NmKGSncHXu[IVv[2V? MkDQNlIzODd2OEW=
ARP-1 MmTPRZBweHSxc3nzJGF{e2G7 MmfoNVDPxE1? Moi3NlRp MlTlSG1UVw>? Mni5bY5lfWOnczDNUUBk\WyuIHHwc5B1d3OrczD0bJJwfWeqIHPhd5Bie2ViYXP0bZZifGmxbh?= MkHpNlIzODd2OEW=
SNU-601 NHT2SnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYC3Nog> M4f3PGROW09? MX3JR|UxRTBwOEG2xtExNjB4M988US=> MlvtNlIyPTl6MUS=
SNU-1 M3PjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\aO|Jp NUXSdYU6TE2VTx?= M3O3d2lEPTB;MT6wPFLDuTBwMEK4{txO MkT4NlIyPTl6MUS=
SNU-668 NX;CfFRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:3Nog> NFvaZllFVVOR NFvGUVJKSzVyPUGuOVc6yrFyLkC3OO69VQ>? NGLtWVYzOjF3OUixOC=>
AGS NVnENHVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV23Nog> NVrW[VhCTE2VTx?= NIHFb5JKSzVyPUGuO|E1yrFyLkGxO:69VQ>? M4XvU|IzOTV7OEG0
SNU-216 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy1OVQ4Omh? NEXuWJVFVVOR MmfITWM2OD1{Lk[5NuKyOC5yOENOwG0> Mk\lNlIyPTl6MUS=
SNU-5 NETKU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVi3Nog> NHfmUlRFVVOR Mki0TWM2OD1zLkO1NeKyOC5yOUJOwG0> MVyyNlE2QThzNB?=
SNU-638 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHxVmE4Omh? M1nvbWROW09? Mkf3TWM2OD1{LkK4NuKyOC5yNUROwG0> Mny3NlIyPTl6MUS=
SNU-16 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq3Nog> MkLVSG1UVw>? MnTTTWM2OD1zLkW3N:KyOC5yMEJOwG0> NFT2[44zOjF3OUixOC=>
SNU-484 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XMcFczcA>? NIX0XFRFVVOR MVLJR|UxRTFwN{K4xtExNjB2Nd88US=> NXPvR2JQOjJzNUm4NVQ>
SNU-620 MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjmO|Jp NGqxcYtFVVOR NWrOO2tkUUN3ME2yMlk{QcLzMD6wNFHPxE1? MnyzNlIyPTl6MUS=
SNU-719 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;kdlczcA>? M2S2T2ROW09? MVfJR|UxRTNwMEO3xtExNjB|Mt88US=> MWiyNlE2QThzNB?=
glioma cell lines NGC0b|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHZO|Jp M2mxUGlEPTB;MT2y{txO NInJVWwzOjB4NUC4NC=>
U87 MoDURZBweHSxc3nzJGF{e2G7 MXOy{txO NWr1foRoPzKq M{SxNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiYX7kJINt\WG4ZXSgVGFTWCCjbnSgZ4F{eGG|ZT2z NGrafowzOjB4NUC4NC=>

... Click to View More Cell Line Experimental Data

体内研究 BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤,完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型,显示抗癌活性。[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型,导致肿瘤体积和K链水平明显降低。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
+ 展开

PI3K 生化实验(ATP 消耗实验):

BKM120溶于DMSO中,按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT,及0.05% CHAPS),然后加到每孔中,随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗,然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟,然后通过荧光测定残留的ATP。
细胞实验:[1]
+ 展开
  • Cell lines: A2780细 胞
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3天
  • Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔103个细胞的密度接种在相同培养基上,温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中,在37oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠
  • Formulation: 15% Captisol
  • Dosages: ~60 mg/kg
  • Administration: 每天口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
5% DMSO+30% PEG 300+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.39
化学式

C18H21F3N6O2

CAS号 944396-07-0
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870726 Completed c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM Novartis Pharmaceuticals|Novartis January 9, 2014 Phase 1|Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT02756247 Recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active, not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)供应商 | 采购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)价格 | Buparlisib (BKM120, NVP-BKM120)生产 | 订购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID